Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

Eli Lilly (LLY) PT Lowered to $973 at Guggenheim

(Updated - January 17, 2025 7:11 AM EST)

Guggenheim analyst Seamus Fernandez lowered the price target on Eli Lilly (NYSE: LLY) to $973.00 (from $995.00) while maintaining a Buy rating.

The analyst commented: "2024 guidance cleanup and 2025 guidance announcement reset expectations and removed stock overhang heading... More

Eli Lilly (LLY) PT Lowered to $970 at Berenberg

Berenberg analyst Kerry Holford lowered the price target on Eli Lilly (NYSE: LLY) to $970.00 (from $1,050.00) while maintaining a Buy rating.... More

Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh is now approved in the... More

Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY) Despite 'Disappointing' GLP-1 Miss

Bernstein SocGen Group analyst Courtney Breen reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented: "LLY Q4 GLP-1 miss disappointing, but long term leadership & TAM remains. This morning Eli Lilly announced 2024 revenue and 2025 guidance. Whilst this will hurt the stock today it doesnt change our long term outlook. 2024 Revenue is expected to be... More

BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,010.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Strong underlying demand persists in the incretin market with pushes and pulls across the company's preliminary 4Q release and 2025 guide. The... More

Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)

Wells Fargo analyst Mohit Bansal reiterated an Overweight rating and $1,000.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "What is new? - This AM Lilly preannounced 4Q numbers and the numbers are weak at $13.5B revs compared to consensus at ~$14B. This appears to be driven by weak Mounjaro and Zepbound portfolio, which stood at $5.4B total compared to $6.5B consensus. Our script tracker was suggesting ~$800M miss for Mounjaro and Zep combined, and it seems as if ex-US/stocking did not come to rescue. Given LLY is talking... More

BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'

BofA Securities analyst Tim Anderson reiterated a Buy rating and $997.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "We think it offers a particularly good buying opportunity. This is predicated on LLY remaining one of two incumbent companies that should... More

Citi Reiterates Buy Rating on Eli Lilly (LLY)

Citi analyst Geoff Meacham reiterated a Buy rating and $1,250.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "We are in SF this week, where Lilly highlighted this mornings disclosure of a Q4 miss (note here) hinged on 1) a typical December... More

Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price pulls back

Eli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 41; compared to its 52-week range of 23 to 55. Call put ratio 1.4 calls to 1 put as share price trends lower.